Investor Firms Seek Lead Plaintiff in Inovio Securities Suit Over Device and FDA Claims

Overview

• The three plaintiff firms, which issued notices Monday, are recruiting investors to seek lead-plaintiff status by April 7, 2026.
• The proposed class covers buyers of Inovio shares from October 10, 2023 through December 26, 2025.
• Complaints say Inovio concealed manufacturing problems with its CELLECTRA delivery device, which the firms allege made a second-half 2024 filing for the INO-3107 biologics application unlikely.
• Filings also claim the company lacked evidence to support FDA priority review or accelerated approval for INO-3107, which the firms say led investors to overestimate the drug’s prospects.
• The suits cite Sections 10(b) and 20(a) and SEC Rule 10b-5, the class is not yet certified, and a Biologics License Application is the FDA’s request to market a biologic that can move faster under priority or accelerated programs.